Inspire Medical Systems, Inc. (INSP) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. At $40.05, A.R:R 1.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak).
Inspire Medical Systems is a medical technology company that makes the Inspire system, the only FDA-approved closed-loop neurostimulation therapy for moderate-to-severe obstructive sleep apnea, treating over 125,000 patients. Revenue is generated by selling the implantable... Read more
Sell if holding. At $40.05, A.R:R 1.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak). Chart setup: Death cross, below all MAs, RSI 19, MACD bearish. Score 5.2/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Inspire Medical Systems, Inc.
Latest news
- Inspire Medical Systems Inc (INSP) Stock Up 4.2% and Still Under - GuruFocus — GuruFocus positive
- Analysts estimate Inspire Medical Systems (INSP) to report a decline in earnings: What to look out for - MSN — MSN neutral
- Inspire Medical Systems (NYSE:INSP) Shares Down 8.3% - Time to Sell? - MarketBeat — MarketBeat negative
- Inspire Medical Systems (INSP) Q1 earnings and revenues top estimates - MSN — MSN positive
- Inspire Medical Systems Earnings Preview: Revenue Expected Flat - IndexBox — IndexBox negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductInspire system10-K Item 1A: 'our dependency on our Inspire system for revenues'
Material Events(8-K, last 90d)
- 2026-05-05Item 5.02LOWStockholders approved the 2026 Omnibus Incentive Plan at the May 7, 2026 Annual Meeting, authorizing 18,793,516 shares. Compensatory arrangement for executives; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $40.05, A.R:R 1.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak). Chart setup: Death cross, below all MAs, RSI 19, MACD bearish. Prior stop was $38.42. Score 5.2/10, moderate confidence.
Take-profit target: $46.40 (+15.9% upside). Prior stop was $38.42. Stop-loss: $38.42.
Concentration risk — Product: Inspire system; Earnings expected to decline ~70% (cyclical peak); Leverage penalty (D/E 3.7): -1.5.
Inspire Medical Systems, Inc. trades at a P/E of 9.1 (forward 30.4). TrendMatrix value score: 6.4/10. Verdict: Sell.
25 analysts cover INSP with a consensus score of 3.6/5. Average price target: $53.
What does Inspire Medical Systems, Inc. do?Inspire Medical Systems is a medical technology company that makes the Inspire system, the only FDA-approved...
Inspire Medical Systems is a medical technology company that makes the Inspire system, the only FDA-approved closed-loop neurostimulation therapy for moderate-to-severe obstructive sleep apnea, treating over 125,000 patients. Revenue is generated by selling the implantable system to hospitals and ASCs in the US and select European markets through a direct sales force; Japan and Singapore use distributors. As of December 31, 2025, the company operated 295 US and 21 international sales territories.